Zarogoulidis Paul, Lampaki Sofia, Chinelis Panos, Lazaridis George, Baka Sofia, Rapti Aggeliki
Pulmonary Department, Oncology Unit, G. Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Oncology Department, G. Papageorgiou University General Hospital, Thessaloniki, Greece.
Med Hypothesis Discov Innov Ophthalmol. 2016 Winter;5(4):132-135.
Lung cancer is still diagnosed during the advanced stage of the disease and most patients do not have the opportunity for surgical treatment, despite the new diagnostic equipment that has been made available in recent years, such as the radial and linear endobronchial ultrasound (EBUS) and electromagnetic fiberoptic bronchoscopy. However, novel targeted therapies with second generation tyrosine kinase inhibitors and immunotherapy are available. In this commentary, we will focus on eye metastasis after initiation of tyrosine kinase inhibitors due to epidermal growth factor mutation of lung cancer adenocarcinoma.
尽管近年来出现了新的诊断设备，如径向和线性支气管内超声（EBUS）以及电磁纤维支气管镜，但肺癌仍在疾病晚期才被诊断出来，大多数患者没有机会接受手术治疗。然而，有第二代酪氨酸激酶抑制剂和免疫疗法等新型靶向治疗方法。在这篇评论中，我们将聚焦于因肺腺癌表皮生长因子突变而开始使用酪氨酸激酶抑制剂后出现的眼部转移。
